Clinical Trials
13 trialsNCT03842228 2026-05-29
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02264678 2026-05-12
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
AstraZeneca
Phase 1 Active not recruiting
NCT00777582 2026-05-08
Phase I Comparative Bioavailability Study
AstraZeneca
Phase 1 Active not recruiting
NCT04197713 2026-04-29
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06545942 2026-04-17
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Active not recruiting
NCT03162627 2026-04-15
Selumetinib and Olaparib in Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03923270 2026-04-01
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT03742245 2026-03-16
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT03641755 2026-02-23
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02208375 2025-12-31
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02546661 2025-12-29
BISCAY
AstraZeneca
Phase 1 Active not recruiting
NCT03874884 2025-05-14
LuPARP
Peter MacCallum Cancer Centre, Australia
Phase 1 Active not recruiting
NCT05358639 2024-11-18
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
Sunnybrook Health Sciences Centre
Phase 1 Active not recruiting